share_log

This Cancer Focused Stock Has 60% Potential Upside, Bullish Analyst Says

This Cancer Focused Stock Has 60% Potential Upside, Bullish Analyst Says

看漲分析師表示，這隻專注於癌症的股票有60%的潛在上行空間
Benzinga Real-time News ·  2022/09/12 14:22
  • HC Wainwright initiated coverage on Rain Therapeutics Inc (NASDAQ:RAIN), with a price target of $10 with a Buy rating.
  • With an upside of almost 60%, the analyst believes Rain's lead asset, milademetan, has the potential to become a tumor-agnostic therapy for MDM2 amplified cancers.
  • Milademetan, in-licensed from Daiichi Sankyo (OTC:DSNKY) in 2020, is an oral MDM2 inhibitor that reactivates the tumor suppressor gene, p53.
  • P53 is a key regulator of various cellular processes, including the cell cycle, DNA repair, and apoptosis.
  • Milademetan could address p53 inactivation across multiple p53 wild-type (WT) tumor types, representing about 50% of all cancers.
  • Rain is conducting a Phase 3 MANTRA trial in patients with well-differentiated / de-differentiated liposarcoma.
  • Since the primary endpoint is based on a doubling of PFS, we believe Rain's Phase 1 data de-risks the upcoming Phase 3 data, slated for release in 1H23, writes HC Wainwright.
  • The analyst conservatively projects that milademetan could have a peak annual sales potential of nearly $1 billion from liposarcoma, non-small cell lung cancer (NSCLC), and breast cancer indications.
  • Price Action: RAIN shares are up 12.60% at $6.42 on the last check Monday.
  • HC Wainwright在以下日期開始覆蓋RAIN治療公司(納斯達克：RAIN)，目標價為10美元，評級為買入。
  • 這位分析師認為，憑藉近60%的上漲，Rain的主要資產Milademetan有可能成為治療MDM2擴增癌症的腫瘤不可知療法。
  • Milademetan，授權自第一三共(場外交易代碼：DSNKY)於2020年推出，是一種口服MDM2抑制劑，可重新激活腫瘤抑制基因p53。
  • P53是多種細胞過程的關鍵調節因子，包括細胞週期、DNA修復和細胞凋亡。
  • Milademetan可以解決多種p53野生型(WT)腫瘤類型中的p53失活問題，這些腫瘤約佔所有癌症的50%。
  • RAIN正在對高分化/去分化脂肪肉瘤患者進行曼陀羅3期試驗。
  • 由於主要終端基於PFS的加倍，我們認為Rain的第一階段數據降低了即將到來的第三階段數據的風險，該數據定於23年上半年發佈，HC Wainwright寫道。
  • 這位分析師保守地預測，米拉西坦在脂肪肉瘤、非小細胞肺癌(NSCLC)和乳腺癌適應症方面的年銷售額可能達到近10億美元的峯值。
  • 價格行動：RAIN股價在週一的最後一次檢查中上漲12.60%，至6.42美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論